Table 6 Association of SOX2 and OCT3/4 expression with demographic, clinical, and laboratory data of AML patients
From: Significance of OCT3/4 and SOX2 antigens expression by leukemic blast cells in adult acute leukemia
Parameter | SOX2 expression (%)Median (min–max) | OCT3/4 expression( %)Median (min–max) | P1 | P2 | |
|---|---|---|---|---|---|
Gender | Male | 25.5 (0.6–81.8) | 1.7 (0.2–14.0) | 0.877 | 0.795 |
Female | 25.8 (0.1–71.9) | 1.6 (0.1–8.8) | |||
CD34% | Negative | 14.9 (0.1–79.1) | 1.2 (0.1–6.5) | 0.066 | 0.133 |
Positive | 30.9 (1–81.8) | 1.7 (0.2–14.0) | |||
FAB Subtypes | M1-M2 | 32.7 (1.0–71.9) | 1.7 (0.5–10.7) | 0.351 | 0.588 |
M3 | 7.3 (0.1–78.9) | 3.4 (0.1–14.0) | |||
M4-M5 | 23.5 (0.6–81.8) | 1.3 (0.2–8.8) | |||
Risk stratification | Favorable | 11.5 (0.1–26.9) | 0.5 (0.1–5.3) | < 0.001 | 0.003 |
Intermediate | 25.5 (9.6–79.1) | 1.7 (0.4–6.5) | |||
Poor | 53.4 (24.7–81.8) | 2.3 (0.5–14.0) | |||
Response | CR | 16.7 (0.1–79.1) | 1.34 (0.1–6.5) | < 0.001 | 0.006 |
Non-CR | 54.5 (24.7–81.8) | 2.3 (0.5–14.0) | |||
Relapse | Non relapsed | 12.7 (0.1–65.0) | 0.5 (0.1–6.5) | 0.045 | < 0.001 |
Relapsed | 24.5 (6.9–79.1) | 2.0 (0.8–5.7) | |||
Living status | Lived | 11.5 (0.1–79.1) | 0.7 (0.1–5.7) | < 0.001 | 0.012 |
Dead | 35.1 (9.6–81.8) | 1.9 (0.2–14.0) | |||